Arcus Biosciences, Inc.
NYSE:RCUS
Overview | Financials
Company Name | Arcus Biosciences, Inc. |
Symbol | RCUS |
Currency | USD |
Price | 15.27 |
Market Cap | 1,397,382,132 |
Dividend Yield | 0% |
52-week-range | 13.52 - 20.31 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Terry J. Rosen Ph.D. |
Website | https://www.arcusbio.com |
An error occurred while fetching data.
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD